International Academy for Clinical Hematology IACH
Published online: 27 February 2020
IACH 2019: Welcome
Share
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about […]
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The CASCADE trial aims to assess the efficacy and safety of pegcetacoplan in patients with cold agglutinin disease (CAD). In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the CASCADE trial ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Cold agglutinin disease (CAD) is a rare, autoimmune, clonal B cell disorder. In this touchONCOLOGY interview, we speak with Dr Bernd Jilma (Medical University of Vienna, Vienna, Austria) to discuss the pathophysiology of CAD and the unmet treatment needs in ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Momelotinib, an oral JAK1/JAK2/ACVR1 inhibitor, was evaluated in 3 randomised controlled trials - SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, in patients with high- and intermediate-risk myelofibrosis. In this touchONCOLOGY interview, we speak with Prof. Srdan Verstovsek (MD Anderson Cancer Center, Houston, ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Studies have linked recurrent miscarriage with inherited thrombophilia. The ALIFE 2 trial aimed to assess the efficacy of low-molecular-weight heparin (LMWH) therapy in women with recurrent miscarriage and inherited thrombophilia. In this touchONCOLOGY interview, we speak with Professor Saskia Middeldorp (Radboud ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Dr Spero R Cataland (The Ohio State University, Wexner Medical Centre, Columbus, OH, USA) joins us for Rare Disease Day to discuss the importance of rapid diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood disorder in which blood ...
Mark CompleteCompleted
BookmarkBookmarked
We had the pleasure to talk to Steven Pipe (University of Michigan, Ann Arbor, MI, USA) to discuss the use of gene therapy for the treatment of haemophilia B. The abstract 'First Data from the Phase 3 HOPE-B Gene Therapy Trial: ...
Mark CompleteCompleted
BookmarkBookmarked
touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at EHA25 Virtual to discuss the ANDROMEDA study (NCT03201965), and the efficacy and safety of daratumumab in combination with CYBORD ...
Mark CompleteCompleted
BookmarkBookmarked
Dr George Goshua (Yale University School of Medicine, New Haven, CT, USA) shares with us his insights into the role of endotheliopathy in the development of coagulopathy in patients with COVID-19. Questions: 1. How common is coagulopathy in COVID-19 infection and ...
Mark CompleteCompleted
BookmarkBookmarked
The International Academy for Clinical Hematology (IACH) welcomes you to attend the 1st Online Master class in Transplantation and Hematology (MATH) Saturday, June 6, 2020 For more information, click here.
Mark CompleteCompleted
BookmarkBookmarked
The 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH): Focus on Leukemia October 1-3, 2020 Nice, France. Published Online: 24 February 2020...
Mark CompleteCompleted
BookmarkBookmarked
Speaker Prof. James Bussel Learning objectives - Understand that thrombopoietic agents (TPO) impacts the stem cell and thus can have trilineage effects - Recognize that TPO agents are an important way to increase the platelet count in patients with inherited ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
